23:07 , May 14, 2019 |  BC Extra  |  Company News

Management tracks: DBV, Beam, Aeon Biopharma

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said Deputy CEO and Principal Financial Officer David Schilansky will leave the company in August to pursue other opportunities. The allergy company is searching for a new CFO but will...
19:56 , Aug 10, 2018 |  BC Extra  |  Company News

Management tracks: Oncopeptides, Merz

Cancer company Oncopeptides AB (SSE:ONCO) said CFO Birgitta Ståhl has stepped down. She is succeeded by Anders Martin-Löf, effective November. He was CFO at medical software company RaySearch Laboratories AB (Stockholm, Sweden) as well as...
02:31 , May 18, 2018 |  BC Week In Review  |  Clinical News

FDA frowns on Evolus

Evolus Inc. (NASDAQ:EOLS) said FDA issued a complete response letter for a BLA for prabotulinumtoxinA (DWP-450) to treat adults with glabellar lines (frown lines between the eyebrows). Evolus shed over $90 million in market cap...
16:48 , May 16, 2018 |  BC Extra  |  Company News

FDA frowns on Evolus

Evolus Inc. (NASDAQ:EOLS) fell $3.95 (27%) to $10.70 on Wednesday after it said FDA issued a complete response letter for a BLA for prabotulinumtoxinA (DWP-450) to treat adults with glabellar lines (frown lines between the...
22:36 , Feb 9, 2018 |  BioCentury  |  Finance

Elites always welcome

The fact that 69 biotechs have raised $6.1 billion via IPO financings on NASDAQ since the start of 2016 might suggest the IPO window has remained wide open in the U.S. A closer look at...
16:24 , Feb 9, 2018 |  BC Week In Review  |  Financial News

Evolus prices $60M IPO

Medical aesthetics company Evolus Inc. (NASDAQ:EOLS) raised $60 million on Feb. 8 through the sale of 5 million shares at $12 in an IPO underwritten by Cantor Fitzgerald, Mizuho, SunTrust Robinson Humphrey and JMP Securities....
20:19 , Feb 8, 2018 |  BC Extra  |  Financial News

Evolus slips after $60M IPO

Evolus Inc. (NASDAQ:EOLS) dipped $0.40 to $11.60 in its first day of trading Thursday after raising $60 million through the sale of 5 million shares at $12 in an IPO underwritten by Cantor Fitzgerald, Mizuho,...
18:57 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

Evolus reports Phase III data for prabotulinumtoxinA in glabellar lines

In October, the Evolus Inc. unit of the Alphaeon Corp. subsidiary of Strathspey Crown Holdings LLC (Newport Beach, Calif.) reported data from 654 patients with glabellar lines (frown lines between the eyebrows) in the Phase...
16:42 , Aug 4, 2017 |  BC Week In Review  |  Clinical News

FDA, EMA to review Strathspey's DWP-450 for glabellar lines

FDA and EMA each accepted for review applications for DWP-450 from the Alphaeon Corp. subsidiary of Strathspey Crown Holdings LLC (Newport Beach, Calif.) to treat adults with glabellar lines, also known as frown lines between...
19:50 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

Strathspey's Alphaeon subsidiary submits BLA to FDA for frown lines candidate

The Alphaeon Corp. subsidiary of Strathspey Crown Holdings LLC (Newport Beach, Calif.) said that its Evolus Inc. unit submitted a BLA to FDA for DWP-450 to treat adults with glabellar lines, also known as frown...